share_log

Biodexa Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Biodexa Pharmaceuticals | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Biodexa Pharmaceuticals | 6-K:外國發行人報告
美股SEC公告 ·  08/30 16:43

Moomoo AI 已提取核心訊息

Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company listed on NASDAQ under the ticker BDRX, has received a Staff Determination letter from Nasdaq on August 27, 2024, indicating the company's securities are at risk of delisting. The reason cited is a closing bid price below $1.00 for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). Biodexa is ineligible for the usual 180-day compliance period due to prior reverse stock splits with a cumulative ratio exceeding 250 to one. The company plans to appeal the decision by requesting a hearing before a Hearings Panel, which will stay any suspension or delisting actions until the hearing and any subsequent extension period concludes. Biodexa specializes in developing treatments for diseases with unmet medical needs, with key programs including eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for rare/orphan brain cancer. The company is headquartered in Cardiff, UK, and emphasizes its commitment to innovative drug delivery technologies.
Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company listed on NASDAQ under the ticker BDRX, has received a Staff Determination letter from Nasdaq on August 27, 2024, indicating the company's securities are at risk of delisting. The reason cited is a closing bid price below $1.00 for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). Biodexa is ineligible for the usual 180-day compliance period due to prior reverse stock splits with a cumulative ratio exceeding 250 to one. The company plans to appeal the decision by requesting a hearing before a Hearings Panel, which will stay any suspension or delisting actions until the hearing and any subsequent extension period concludes. Biodexa specializes in developing treatments for diseases with unmet medical needs, with key programs including eRapa for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, tolimidone for type 1 diabetes, and MTX110 for rare/orphan brain cancer. The company is headquartered in Cardiff, UK, and emphasizes its commitment to innovative drug delivery technologies.
Biodexa Pharmaceuticals PLC,一家在納斯達克上市的處於臨床階段的生物製藥公司,在2024年8月27日收到了納斯達克的工作人員決定函,表明公司的證券存在被退市的風險。原因是股價連續30個營業日低於1.00美元的收盤買盤價,違反了納斯達克5000條規定(a)(2)。由於之前進行了累積比例超過250比1的逆拆股並股,Biodexa無法獲得通常的180天合規期。該公司計劃通過請求在聽證會議前請求聽證小組審理來上訴該決定,這將使得在聽證會議以及任何隨後的延期期間之前暫時停止任何停牌或退市行動。Biodexa專注於開發治療存在醫療需求的疾病的產品,其主要項目包括適用於家族腺瘤性息肉症和非肌肉侵襲性膀胱癌的eRapa,適用於1型糖尿病的tolimidone,以及適用於罕見/孤兒腦癌的MTX110。公司總部位於英國卡迪夫,強調其對創新藥物遞送技術的承諾。
Biodexa Pharmaceuticals PLC,一家在納斯達克上市的處於臨床階段的生物製藥公司,在2024年8月27日收到了納斯達克的工作人員決定函,表明公司的證券存在被退市的風險。原因是股價連續30個營業日低於1.00美元的收盤買盤價,違反了納斯達克5000條規定(a)(2)。由於之前進行了累積比例超過250比1的逆拆股並股,Biodexa無法獲得通常的180天合規期。該公司計劃通過請求在聽證會議前請求聽證小組審理來上訴該決定,這將使得在聽證會議以及任何隨後的延期期間之前暫時停止任何停牌或退市行動。Biodexa專注於開發治療存在醫療需求的疾病的產品,其主要項目包括適用於家族腺瘤性息肉症和非肌肉侵襲性膀胱癌的eRapa,適用於1型糖尿病的tolimidone,以及適用於罕見/孤兒腦癌的MTX110。公司總部位於英國卡迪夫,強調其對創新藥物遞送技術的承諾。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息